CoChat

Depression in type 1 diabetes was associated with high levels of circulating galectin-3

Open access

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

Objective: Neuroinflammatory responses are implicated in depression. The aim was to explore whether depression in patients with type 1 diabetes (T1D) was associated with high circulating galectin-3, controlling for metabolic variables, s-creatinine, life style factors, medication and cardiovascular complications. Design: Cross-sectional. Methods: Participants were T1D patients ( n = 283, 56% men, age 18–59 years, diabetes duration ≥1 year). Depression was assessed by Hospital Anxiety and Depression Scale-depression subscale. Blood samples, anthropometrics and blood pressure were collected, and supplemented with data from medical records and the Swedish National Diabetes Registry. Galectin-3 ≥2.562 µg/l, corresponding to the 85th percentile, was defined as high galectin-3. Results: Median (quartile 1 , quartile 3 ) galectin-3 (µg/l) was 1.3 (0.8, 2.9) for the 30 depressed patients, and 0.9 (0.5, 1.6) for the 253 non-depressed, P = 0.009. Depression was associated with high galectin-3 in all the 283 patients (adjusted odds ratio (AOR) 3.5), in the 161 men (AOR 3.4), and in the 122 women (AOR 3.9). HbA1c, s-lipids, s-creatinine, blood pressure, obesity, smoking, physical inactivity, cardiovascular complications and drugs (antihypertensive, lipid lowering, oral antidiabetic drugs and antidepressants) were not associated with high galectin-3. Conclusions: This is the first study to show an association between depression and galectin-3. Depression was the only explored parameter associated with high circulating galectin-3 levels in 283 T1D patients. High galectin-3 levels might contribute to the increased risk for Alzheimer’s disease, cardiovascular and all-cause mortality observed in persons with depression. Potentially, in the future, treatment targeting galactin-3 might improve the prognosis for patients with high galectin-3 levels.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/ec-18-0108

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flowchart describing the 283 included participants, included variables and numbers of missing values.
Figure 1 Flowchart describing the 283 included participants, included variables and numbers of missing values.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 38

  1. Relations of depressive symptoms and antidepressant use to body mass index and selected biomarkers for diabetes and cardiovascular disease https org, American Journal of Public Health, 34
  2. 2012, A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia, Brain, Behavior, and Immunity, 26, 469, 10.1016/j.bbi.2011.12.011 · DOI · Paper page
  3. 2015, Microglia-secreted galectin-3 acts as a toll-like receptor 4 ligand and contributes to microglial activation, Cell Reports, 10, 1626, 10.1016/j.celrep.2015.02.012 · DOI · Paper page
  4. 2014, Depression, smoking, physical inactivity and season independently associated with midnight salivary cortisol in type 1 diabetes, BMC Endocrine Disorders, 14, 75, 10.1186/1472-6823-14-75 · DOI
  5. 2014, Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds, Annual Review of Pharmacology and Toxicology, 54, 119, 10.1146/annurev-pharmtox-011613-135950 · DOI · Paper page
  6. 2013, Increased serum matrix metalloproteinase-9 (MMP-9) levels in young patients during bipolar depression, Journal of Affective Disorders, 146, 286, 10.1016/j.jad.2012.07.019 · DOI
  7. 2016, Affect school and script analysis versus basic body awareness therapy in the treatment of psychological symptoms in patients with diabetes and high HbA1c concentrations: two study protocols for two randomized controlled trials, Trials, 17, 221, 10.1186/s13063-016-1347-8 · DOI
  8. 2013, Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure, Archives of Cardiovascular Diseases, 106, 541, 10.1016/j.acvd.2013.06.054 · DOI
  9. 2015, Extracellular galectin-3 induces MMP9 expression by activating p38 MAPK pathway via lysosome-associated membrane protein-1 (LAMP1), Molecular and Cellular Biochemistry, 404, 79, 10.1007/s11010-015-2367-5 · DOI
  10. 2010, Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections, PLoS ONE, 5, e9166, 10.1371/journal.pone.0009166 · DOI · Paper page
  11. 2013, Depression, obesity and smoking were independently associated with inadequate glycemic control in patients with type 1 diabetes, European Journal of Endocrinology, 168, 861, 10.1530/eje-13-0137 · DOI · Paper page
  12. 2017, Depression differed by midnight cortisol secretion, alexithymia and anxiety between diabetes types: a cross sectional comparison, BMC Psychiatry, 17, 335, 10.1186/s12888-017-1495-8 · DOI
  13. MarioU, Role of galectin as a receptor for advanced glycosylation end products https org, Kidney International, 200058, 10.1046/j.1523-1755.2000.07706.x · DOI
  14. 2006, Cytokines sing the blues: inflammation and the pathogenesis of depression, Trends in Immunology, 27, 24, 10.1016/j.it.2005.11.006 · DOI · Paper page
  15. 2017, Gender, alexithymia and physical inactivity associated with abdominal obesity in type 1 diabetes mellitus: a cross sectional study at a secondary care hospital diabetes clinic, BMC Obesity, 4, 21, 10.1186/s40608-017-0157-1 · DOI
  16. 2014, A validation study of the Hospital Anxiety and Depression Scale (HADS) in a large sample of French employees, BMC Psychiatry, 14, 1
  17. 1983, The hospital anxiety and depression scale, Acta Psychiatrica Scandinavica, 67, 361, 10.1111/j.1600-0447.1983.tb09716.x · DOI · Paper page
  18. 1994, Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and-9, Biochemistry, 33, 14109, 10.1021/bi00251a020 · DOI · Paper page
  19. 2007, Glycemic and risk factor control in type 1 diabetes, Diabetes Care, 30, 496, 10.2337/dc06-1406 · DOI · Paper page
  20. 2010, Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes, Journal of Clinical Endocrinology and Metabolism, 95, 1404, 10.1210/jc.2009-1619 · DOI · Paper page
  21. 2016, Determinants of temporal changes in galectin-3 level in the general population: data of PREVEND, International Journal of Cardiology, 222, 385, 10.1016/j.ijcard.2016.07.241 · DOI
  22. 2005, Depression and all-cause and coronary heart disease mortality among adults with and without diabetes, Diabetes Care, 28, 1339, 10.2337/diacare.28.6.1339 · DOI · Paper page
  23. 2013, The pleiotropic effects of galectin-3 in neuroinflammation: a review, Acta Histochemica, 115, 407, 10.1016/j.acthis.2012.11.010 · DOI
  24. 2011, Type 1 diabetes mellitus and major depressive disorder: evidence for a biological link, Diabetologia, 54, 2483, 10.1007/s00125-011-2240-3 · DOI
  25. 2017, Tissue-and cell-specific localization of galectins, β-galactose-binding animal lectins, and their potential functions in health and disease, Anatomical Science International, 92, 25, 10.1007/s12565-016-0366-6 · DOI
  26. 2009, Matrix metalloproteinase-9 controls NMDA receptor surface diffusion through integrin β1 signaling, Journal of Neuroscience, 29, 6007, 10.1523/jneurosci.5346-08.2009 · DOI · Paper page
  27. WangBAnXShiXZhangJ OF DISEASE Suicide risk in patients with diabetes a systematic review and meta - analysis of https org, MANAGEMENT ENDOCRINE European Journal Endocrinology, 2017177, 10.1530/eje-16-0952 · DOI · Paper page
  28. 2015, Elevated galectin-3 levels in the serum of patients with Alzheimer’s disease, American Journal of Alzheimer’s Disease and Other Dementias, 30, 729, 10.1177/1533317513495107 · DOI · Paper page
  29. 2014, Glycemic control and excess mortality in type 1 diabetes, New England Journal of Medicine, 371, 1972, 10.1056/nejmoa1408214 · DOI · Paper page
  30. 2013, Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile, BMC Medicine, 11, 129, 10.1186/1741-7015-11-129 · DOI · Paper page
  31. 2012, Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases?, Clinical Biochemistry, 45, 719, 10.1016/j.clinbiochem.2012.04.009 · DOI
  32. 2004, Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction, Circulation, 110, 3121, 10.1161/01.cir.0000147181.65298.4d · DOI · Paper page
  33. 2011, Matrix metalloproteinases contribute to neuronal dysfunction in animal models of drug dependence, Alzheimer’s disease, and epilepsy, Biochemistry Research International, 2011, 681385
  34. 2017, Meta-analysis of the usefulness of plasma galectin-3 to predict the risk of mortality in patients with heart failure and in the general population, American Journal of Cardiology, 119, 57, 10.1016/j.amjcard.2016.09.019 · DOI
  35. 2014, LDL cholesterol: controversies and future therapeutic directions, Lancet, 384, 607, 10.1016/s0140-6736(14)61009-6 · DOI · Paper page
  36. 2017, Galectin-3 released in response to traumatic brain injury acts as an alarmin orchestrating brain immune response and promoting neurodegeneration, Scientific Reports, 7, 41689, 10.1038/srep41689 · DOI · Paper page
  37. 2012, Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community, Journal of the American College of Cardiology, 60, 1249, 10.1016/j.jacc.2012.04.053 · DOI · Paper page
  38. 2016, Estimating the proportion of metabolic health outcomes attributable to obesity: a cross-sectional exploration of body mass index and waist circumference combinations, BMC Obesity, 3, 4, 10.1186/s40608-016-0085-5 · DOI

Cited by

See all 34

Metadata

Authors
Melin, E. O., Dereke, J., Thunander, M., & Hillman, M.
Affiliations
Lund University (SE)
Corresponding author
Melin, Eva Olga
Venue
Endocrine Connections
Published
2018-06
Volume
7
Issue
6
Pages
819-828
ISSN
2049-3614 (ISSN-L)
OpenAlex
W2805013969
Cited by
31
References
41
Citations by year
2026: 1 · 2025: 4 · 2023: 2 · 2022: 7 · 2021: 5 · 2020: 5 · 2019: 6 · 2018: 1
FWCI
1.83
Type
journal article
Language
en
Open access
Locations
  • Endocrine Connections (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • Forskningsrådet i Sydöstra Sverige
  • Lunds Universitet
  • Region Kronoberg
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Galectins and Cancer Biology
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
depression, type 1 diabetes, galectin-3, circulating biomarkers, neuroinflammation, Alzheimer's disease risk, cardiovascular complications, mortality risk, sex differences

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.